Tag: Arkbio Announces
-
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
SHANGHAI, Oct. 13, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to…
Latest News
About the Author
Your reliable go-to for precise and up-to-date information!
We are dedicated to accuracy, impartiality, and providing news as it unfolds, earning the trust of a wide audience. Keep up with real-time updates on the latest events and trends.